膜杰作
Star Staining
- Genetically modified cell lines best reflect MOA (Mechanism of Action)
- Higher activity and larger assay window for robust and reproducible cell-based bioassay
- Comprehensive application data to support assay development and validation
- Full tracible record, stringent quality control and validated cell passage stability
- Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
- Global commercial license assistance whenever regulatory filing is required
描述（Description）
The Human THRA (Luc) HEK293 Reporter Cell was engineered to not only express thyroid hormone response element (TRE), but also express the receptor full length human THRA (Gene ID: 7067), which can drive luciferase expressing systems by thyroid hormone (TH) or thyroid hormone receptor (THR) agonists stimulation. In the absence of TH or THR agonists, the THRA receptor is not activated and luminescence signal is low. In the presence of TH or THR agonists, the THRA pathway-activated luminescence can be detected in a dose-dependent manner.
应用说明（Application）
• Screen for THR-β-selective agonists.
生长特性（Growth Properties）
Adherent
筛选标记（Selection Marker）
Puromycin (2 μg/mL) + Hygromycin (20 μg/mL)
培养基（Culture Medium）
DMEM + 10% FBS
冻存液（Freeze Medium）
Serum-free cell cryopreservation medium
装量（Quantity）
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存储（Storage）
Frozen in liquid nitrogen.
支原体检测（Mycoplasma Testing）
Negative
无菌检测（Sterility Testing）
Negative
使用说明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
Application
Bioactivity analysis of THR-β-selective agonist (RLU).
The Human THRA (Luc) HEK293 Reporter Cell and Human THRB (Luc) HEK293 Reporter Cell (Cat. No. CHEK-ATF181) were incubated with serial dilutions of Resmetirom (a THR-β-selective agonist), respectively. The EC50 of Resmetirom determined on Human THRB (Luc) HEK293 Reporter Cell was approximately 5.5 μM.
Protocol
Bioactivity analysis of THR-β-selective agonist (FOLD).
The Human THRA (Luc) HEK293 Reporter Cell and Human THRB (Luc) HEK293 Reporter Cell (Cat. No. CHEK-ATF181) were incubated with serial dilutions of Resmetirom (a THR-β-selective agonist), respectively. The max induction fold of Resmetirom determined on Human THRB (Luc) HEK293 Reporter Cell was approximately 31.96, and on Human THRA (Luc) HEK293 Reporter Cell was approximately 1.92, which exhibited higher potency and selectivity for THR-β over THR-α.
Protocol
Signaling Bioassay
Response to thyroid hormone (RLU).
This reporter cell was incubated with serial dilutions of Liothyronine (a dual THR-α and THR-β agonist). The EC50 of Liothyronine was approximately 0.0049 μM.
Protocol
Response to thyroid hormone (FOLD).
This reporter cell was incubated with serial dilutions of Liothyronine (a dual THR-α and THR-β agonist). The max induction fold was approximately 10.88.
Protocol
如有相关细胞池需求请联系我们
背景（Background）
Nuclear hormone receptor that can act as a repressor or activator of transcription. High affinity receptor for thyroid hormones, including triiodothyronine and thyroxine.
Limited Use&License Disclosure
- This cell line is provided for research use only. It is neither intended for any animal or human therapeutic use nor for any direct human in vivo use. You are restricted to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
- ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
- ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
- Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order.cn@acrobiosystems.com for further details.
